As a BCL-2 inhibitor with high oral bioavailability and high specificity for BCL-2, venetoclax is able to markedly inhibit the survival of BCL-2-dependent hematological tumors without affecting platelets, providing high hopes for clinical practicability [11]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.